ShingrixⓇ: An Overview for Pharmacists
​
Elizabeth Claus, Paige Hoffman, Vivian Lee
Abstract
 ShingrixⓇ is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. This subunit vaccine is approved for the prevention of herpes zoster also known as shingles. A quarter of the population is at risk of developing herpes zoster during their lifetime and two thirds of people with the disease are aged 50 years or older.1 With the rise in adults aged 50 years or older in the United States due to the aging “baby boomer” generation, it is important that health care providers are properly educated and armed with the information that is needed to understand, educate and administer the ShingrixⓇ vaccination for their patients. It is important that healthcare professionals are comfortable navigating the challenges that result from the novelty of a new herpes zoster vaccine in order to ensure that their patients are effectively covered.
Full Text
Shingrix.pdf
File Size: 290 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH